title: Fusion-expressed CTB improves both systemic and mucosal T-cell responses elicited by an intranasal DNA priming/intramuscular recombinant vaccinia boosting regimen.
abstract: Previous study showed that CTB (Cholera toxin subunit B) can be used as a genetic adjuvant to enhance the systemic immune responses. To further investigate whether it can also be used as a genetic adjuvant to improve mucosal immune responses, we constructed DNA and recombinant Tiantan vaccinia (rTTV) vaccines expressing OVA-CTB fusion antigen. Female C57BL/6 mice were immunized with an intranasal DNA priming/intramuscular rTTV boosting regimen. OVA specific T-cell responses were measured by IFN-γ ELISPOT and specific antibody responses were determined by ELISA. Compared to the nonadjuvant group (pSV-OVA intranasal priming/rTTV-OVA intramuscular boosting), pSV-OVA-CTB intranasal priming/rTTV-OVA-CTB intramuscular boosting group significantly improved the magnitudes of T-cell responses at spleen (1562 ± 567 SFCs/10(6) splenocytes versus 330 ± 182 SFCs/10(6) splenocytes, P < 0.01), mesenteric LN (96 ± 83 SFCs/10(6) lymphocytes versus 1 ± 2 SFCs/10(6) lymphocytes, P < 0.05), draining LNs of respiratory tract (109 ± 60 SFCs/10(6) lymphocytes versus 2 ± 2 SFCs/10(6) lymphocytes, P < 0.01) and female genital tract (89 ± 48 SFCs/10(6) lymphocytes versus 23 ± 21 SFCs/10(6) lymphocytes, P < 0.01). These results collectively demonstrated that fusion-expressed CTB could act as a potent adjuvant to improve both systemic and mucosal T-cell responses.
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Sugan
authors.initials: S
authors.lastname: Qiu
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Ren
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Yinyin
authors.initials: Y
authors.lastname: Ben
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Yanqin
authors.initials: Y
authors.lastname: Ren
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China ; Institute of Biomedical Science, Fudan University, Shanghai 200032, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China ; Institute of Biomedical Science, Fudan University, Shanghai 200032, China.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
authors.forename: Yanmin
authors.initials: Y
authors.lastname: Wan
authors.affiliation: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China ; Institute of Biomedical Science, Fudan University, Shanghai 200032, China.
authors.forename: Jianqing
authors.initials: J
authors.lastname: Xu
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000906:Antibodies / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D002772:Cholera Toxin / Q000235:genetics / Q000276:immunology*; D005260:Female; D005836:Genitalia, Female / Q000276:immunology; D007109:Immunity; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D007273:Injections, Intramuscular; D008198:Lymph Nodes / Q000276:immunology; D051379:Mice; D010047:Ovalbumin / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D012137:Respiratory System / Q000276:immunology; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage
chemical_list: D000906:Antibodies; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; D010047:Ovalbumin; D002772:Cholera Toxin
references.citation: Int Rev Immunol. 2003 Jan-Feb;22(1):43-63
references.pmid: 12710503
references.citation: Mol Cells. 2003 Aug 31;16(1):106-12
references.pmid: 14503853
references.citation: Indian J Med Res. 2011 Feb;133:153-63
references.pmid: 21415489
references.citation: Clin Vaccine Immunol. 2011 Jun;18(6):922-30
references.pmid: 21508173
references.citation: Infect Immun. 2002 Jun;70(6):2741-51
references.pmid: 12010958
references.citation: Nat Med. 2005 Apr;11(4 Suppl):S45-53
references.pmid: 15812489
references.citation: Parasit Vectors. 2013 Mar 13;6:63
references.pmid: 23497561
references.citation: Nat Rev Immunol. 2006 Feb;6(2):148-58
references.pmid: 16491139
references.citation: J Immunol. 1984 Dec;133(6):2892-7
references.pmid: 6491278
references.citation: J Immunol. 1984 Oct;133(4):1818-24
references.pmid: 6470484
references.citation: Curr Gene Ther. 2011 Dec;11(6):479-84
references.pmid: 22023477
references.citation: Vaccine. 2007 Mar 30;25(14):2620-9
references.pmid: 17280743
references.citation: Scand J Immunol. 1990 Apr;31(4):443-51
references.pmid: 2333468